C. Kainz et al., IMMUNOHISTOCHEMICAL DETECTION OF ADHESION MOLECULE CD44 SPLICE VARIANTS IN LYMPH-NODE METASTASES OF CERVICAL-CANCER, International journal of cancer, 69(3), 1996, pp. 170-173
Expression of specific cell adhesion molecule CD44 isoforms (splice va
riants) has been shown to be associated with poor prognosis in human c
ervical cancer. We used 3 different variant exon sequence-specific mur
ine monoclonal antibodies (MAbs) to epitopes encoded by exons v5, v6 a
nd v7-v8 of human variant CD44 to study the expression of CD44 splice
variants in 35 primary squamous-cell carcinomas of the cervix and pelv
ic lymph node metastases by means of immunohistochemistry. Primary tum
ors showed expression of CD44 splice variants CD44v5, CD44v6 and CD44v
7-8 in 93%, 73% and 33% of cases, respectively. Lymph node metastases
expressed CD44v5, CD44v6 and CD44v7-8 in 83%, 53% and 21% of cases, re
spectively. Tumors with expression of CD44v6 in pelvic lymph node meta
stases showed metastatic spread to 2 or more pelvic lymph nodes signif
icantly more often compared to patients without expression of splice v
ariant CD44v6. Patients suffering from tumors with lymph node metastas
es expressing splice variant CD44v6 had a poorer recurrence-free survi
val compared to patients without CD44v6 expression in lymph node metas
tases, but this trend was not statistically significant. Expression of
CD44 splice variants containing epitopes encoded by exon v6 in primar
y tumors and pelvic lymph node metastases of cervical cancer patients
is consistent with a prominent role of CD44 in the process of metastas
is formation. (C) 1996 Wiley-Liss, Inc.